The stock of SCYNEXIS Inc (NASDAQ:SCYX) is a huge mover today! The stock increased 4.23% or $0.15 on November 23, hitting $3.7. About 213,365 shares traded hands. SCYNEXIS Inc (NASDAQ:SCYX) has declined 11.48% since April 22, 2016 and is downtrending. It has underperformed by 16.89% the S&P500.
The move comes after 6 months positive chart setup for the $85.63M company. It was reported on Nov, 24 by Barchart.com. We have $3.92 PT which if reached, will make NASDAQ:SCYX worth $5.14 million more.
Analysts await SCYNEXIS Inc (NASDAQ:SCYX) to report earnings on March, 6. After $-0.35 actual earnings per share reported by SCYNEXIS Inc for the previous quarter, Wall Street now forecasts 8.57% negative EPS growth.
SCYNEXIS Inc (NASDAQ:SCYX) Ratings Coverage
Out of 6 analysts covering Scynexis Inc (NASDAQ:SCYX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $17 is the highest target while $8.0 is the lowest. The $14.20 average target is 283.78% above today’s ($3.7) stock price. Scynexis Inc has been the topic of 9 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The company was upgraded on Friday, October 7 by WBB Securities. The rating was initiated by Brean Capital on Monday, March 28 with “Buy”. The company was initiated on Wednesday, August 17 by Guggenheim. The company was maintained on Thursday, August 20 by Needham. The firm has “Strong Buy” rating given on Tuesday, December 29 by WBB Securities. The stock of SCYNEXIS Inc (NASDAQ:SCYX) earned “Buy” rating by H.C. Wainwright on Thursday, October 20. The rating was initiated by Brean Capital on Monday, October 3 with “Buy”. The firm has “Outperform” rating given on Monday, November 16 by RBC Capital Markets. The firm has “Buy” rating by WBB Securities given on Tuesday, August 9.
According to Zacks Investment Research, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in Q2 2016. Its down 1.06, from 1.82 in 2016Q1. The ratio dived, as 4 funds sold all SCYNEXIS Inc shares owned while 7 reduced positions. 10 funds bought stakes while 10 increased positions. They now own 13.69 million shares or 61.88% more from 8.46 million shares in 2016Q1.
Fmr Lc has 1.73 million shares for 0% of their US portfolio. California Public Employees Retirement Systems last reported 0% of its portfolio in the stock. Rock Springs Capital Ltd Partnership accumulated 635,000 shares or 0.1% of the stock. Jacobs Levy Equity holds 26,100 shares or 0% of its portfolio. Granite Point Limited Partnership owns 175,000 shares or 0.16% of their US portfolio. Morgan Stanley holds 9,320 shares or 0% of its portfolio. Vanguard Grp Inc has invested 0% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX). Deutsche Bank Ag accumulated 137,649 shares or 0% of the stock. Deerfield Mngmt has 0.15% invested in the company for 1.77M shares. Millennium Mngmt Ltd Com holds 36,700 shares or 0% of its portfolio. Blackrock Fund has 30,090 shares for 0% of their US portfolio. Dafna Cap Mngmt Limited Liability accumulated 266,904 shares or 0.46% of the stock. Royal Fincl Bank Of Canada accumulated 4,300 shares or 0% of the stock. Ladenburg Thalmann Financial Service accumulated 3,156 shares or 0% of the stock. Geode Mgmt Limited Company accumulated 55,168 shares or 0% of the stock.
Insider Transactions: Since May 25, 2016, the stock had 2 insider purchases, and 0 sales for $199,759 net activity. Shares for $82,159 were bought by Angulo Gonzalez David on Wednesday, June 29. 246 shares with value of $787 were bought by Taglietti Marco on Wednesday, May 25. Shares for $117,600 were bought by Machado Patrick. HANHAM ANN bought $15,379 worth of SCYNEXIS Inc (NASDAQ:SCYX) on Wednesday, May 25.
More recent SCYNEXIS Inc (NASDAQ:SCYX) news were published by: Marketwatch.com which released: “SCYNEXIS Inc. NASDAQ: SCYX” on April 23, 2014. Also Quotes.Wsj.com published the news titled: “SCYNEXIS Inc. SCYX (US: Nasdaq)” on March 31, 2014. Globenewswire.com‘s news article titled: “SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides …” with publication date: November 07, 2016 was also an interesting one.
SCYX Company Profile
SCYNEXIS, Inc., incorporated on November 4, 1999, is a pharmaceutical company, which is engaged in the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. It also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. Candida and Aspergillus species are the fungi responsible for all invasive fungal infections in the United States and Europe. The Firm has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.